{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-008062","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.903300+00:00","generated_at":"2026-06-01T02:26:42.892350+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial","bullets":["Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.","Prior Phase 2 study showed paridiprubart reduced mortality by 84% among critically ill COVID-19 ARDS patients.","Edesa's ongoing Phase 3 study of paridiprubart in COVID-19 ARDS continues in Canada and the U.S.","BARDA contract managed via PPD (Thermo Fisher); Edesa supplies drug product and technical support.","Goal is to label paridiprubart as standard-of-care for all-cause ARDS, with biomarker sub-study to inform development."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-008062","json":"https://secwatch.observer/filing/0001654954-24-008062.json","markdown":"https://secwatch.observer/filing/0001654954-24-008062.md","text":"https://secwatch.observer/filing/0001654954-24-008062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424008062/0001654954-24-008062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424008062/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:26:42.892350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}